Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome

Medical Oncology

Volumn 32, Issue 2, 2015, Pages

  Leng, Ruobing ^a   Liao, Gang ^a   Wang, Haixia ^a   Kuang, Jun ^a   Tang, Liangdan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cell migration; EMT; Ovarian cancer; Prognosis; Rac1

Indexed keywords

CA 125 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; P21 ACTIVATED KINASE 1; RAC1 PROTEIN; UVOMORULIN; VIMENTIN; RAC1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRDU ASSAY; CALCIUM BLOOD LEVEL; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; VERY ELDERLY; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XENOGRAFT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RAC1 GTP-BINDING PROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; YOUNG ADULT;

EID: 84938058544     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0329-5     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;50(5):277–300. doi:10.3322/caac.20073.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5(1):19–24.
3. Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer. 2010;46(1):170–9. doi:10.1016/j.ejca.2009.10.003.
4. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):243–56. doi:10.1016/j.bpobgyn.2011.11.006.
5. Kohn EC, Hurteau J. Ovarian cancer: making its own rules-again. Cancer. 2013;119(3):474–6. doi:10.1002/cncr.27833.
6. Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo SC, Kim KH, et al. TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem. 2013;32(2):253–63. doi:10.1159/000354434.
7. Kalra RS, Bapat SA. Expression proteomics predicts loss of RXR-γ during progression of epithelial ovarian cancer. PLoS One. 2013;8(8):e70398. doi:10.1371/journal.pone.0070398.
8. Zhong YC, Zhang T, Di W, Li WP. Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial–mesenchymal transition. J Gynecol Oncol. 2013;24(3):265–72. doi:10.3802/jgo.2013.24.3.265.
9. Shirkoohi R. Epithelial mesenchymal transition from a natural gestational orchestration to a bizarre cancer disturbance. Cancer Sci. 2013;104(1):28–35. doi:10.1111/cas.12074.
10. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin’s dark side: possible role in tumor progression. Biochim Biophys Acta. 2012;1826(1):23–31. doi:10.1016/j.bbcan.2012.03.002.
11. Gallo D, Ferlini C, Scambia G. The epithelial–mesenchymal transition and the estrogen-signaling in ovarian cancer. Curr Drug Targets. 2010;11(4):474–81.
12. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial–mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59–66.
13. Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong L, Yang P. Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken). 2010;293:1134–9. doi:10.1016/j.canlet.2009.09.017.
14. Huang KJ, Sui LH. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol. 2012;29(1):318–23. doi:10.1007/s12032-010-9817-4.
15. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci (Landmark Ed). 2011;1(16):2561–71.
16. Bauer NN, Chen YW, Samant RS, Shevde LA, Fodstad O. Rac1 activity regulates proliferation of aggressive metastatic melanoma. Exp Cell Res. 2007;313(18):3832–9.
17. Santibáñez JF, Kocić J, Fabra A, Cano A, Quintanilla M. Rac1 modulates TGF-beta1-mediated epithelial cell plasticity and MMP9 production in transformed keratinocytes. FEBS Lett. 2010;584(11):2305–10. doi:10.1016/j.febslet.2010.03.042.
18. Lv Z, Hu M, Zhen J, Lin J, Wang Q, Wang R. Rac1/PAK1 signaling promotes epithelial–mesenchymal transition of podocytes in vitro via triggering β-catenin transcriptional activity under high glucose conditions. Int J Biochem Cell Biol. 2013;45(2):255–64. doi:10.1016/j.biocel.2012.11.003.
19. Hage B, Meinel K, Baum I, Giehl K, Menke A. Rac1 activation inhibits E-cadherin-mediated adherens junctions via binding to IQGAP1 in pancreatic carcinoma cells. Cell Commun Signal. 2009;7:23. doi:10.1186/1478-811X-7-23.
20. Zhang J, Tang L, Shen L, Zhou S, Duan Z, Xiao L, et al. High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer. Gynecol Oncol. 2012;127(1):223–30. doi:10.1016/j.ygyno.2012.06.008.
21. Zhou S, Tang L, Wang H, Dai J, Zhang J, Shen L, et al. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer. Gynecol Oncol. 2013;131(1):69–76. doi:10.1016/j.ygyno.2013.06.031.
22. Tahirovic S, Hellal F, Neukirchen D, Hindges R, Garvalov BK, Flynn KC, et al. Rac1 regulates neuronal polarization through the WAVE complex. J Neurosci. 2010;30(20):6930–43. doi:10.1523/JNEUROSCI.5395-09.2010.
23. Karpushev AV, Levchenko V, Ilatovskaya DV, Pavlov TS, Staruschenko A. Novel role of Rac1/WAVE signaling mechanism in regulation of the epithelial Na+ channel. Hypertension. 2011;57(5):996–1002.
24. Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature. 2002;418(6899):790–3. doi:10.1161/HYPERTENSIONAHA.110.157784.
25. Yamazaki D, Oikawa T, Takenawa T. Rac-WAVE-mediated actin reorganization is required for organization and maintenance of cell–cell adhesion. J Cell Sci. 2007;120(Pt 1):86–100.
26. Sanchez AM, Flamini MI, Fu XD, Mannella P, Giretti MS, Goglia L, et al. Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol. 2009;23(8):1193–202. doi:10.1210/me.2008-0408.
27. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, et al. Tyrosine kinase B receptor and BDNF expression in ovarian cancers-effect on cell migration, angiogenesis and clinical outcome. Cancer Lett. 2009;281(2):151–61. doi:10.1016/j.canlet.2009.02.025.
28. Meng Erhong, Taylor Brandon, Ray Anasuya, Shevde LA, Rocconi RP. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol. 2012;124(3):598–605. doi:10.1016/j.ygyno.2011.11.018.
29. Kalfa TA, Pushkaran S, Mohandas N, Hartwig JH, Fowler VM, Johnson JF, et al. Rac GTPases regulate the morphology and deformability of the erythrocyte cytoskeleton. Blood. 2006;108(12):3637–45.
30. Yang WH, Lan HY, Huang CH, Tai SK, Tzeng CH, Kao SY, et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol. 2012;14(4):366–74. doi:10.1038/ncb2455.
31. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000;19(26):3013–20.
32. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, Blaveri E, Baron A, Terris B, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene. 2001;20(50):7437–46.
33. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial–mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59–66. doi:10.1016/j.canlet.2009.09.017.
34. Galan Moya EM, Le Guelte A, Gavard J. PAKing up to the endothelium. Cell Signal. 2009;21(12):1727–37. doi:10.1016/j.cellsig.2009.08.006.
35. Bakin AV, Rinehart C, Tomlinson AK. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci. 2002;115(pt15):3193–206.